Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal CarcinomaJing Huang, Yuchen Jiao, Bo Lan et al.|Clinical Cancer Research|2018Cited by 218
Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 studyHongnan Mo, Binghe Xu, Jing Huang et al.|British Journal of Cancer|2018Cited by 156
Promising efficacy of SHR‐1210, a novel anti–programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in ChinaJing Huang, Binghe Xu, Hongnan Mo et al.|Cancer|2018Cited by 66
[Clinical observation of thyroid-related adverse events induced by anti-PD-1 antibody SHR-1210 in patients with advanced solid tumor].Ling Qi, Jing Huang, Hongnan Mo et al.|PubMed|2018Cited by 2